Exploring the role of inflammation in the malignant transformation of low-grade gliomas

Journal of Neuroimmunology

Volumn 297, Issue , 2016, Pages 132-140

  Michelson, Nicole ^a   Rincon Torroella, Jordina ^a   Quiñones Hinojosa, Alfredo ^a   Greenfield, Jeffrey P ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

IDH1 mutation; Inflammation; Low grade gliomas; Macrophages; Malignant transformation; Microglia

Indexed keywords

AUTACOID; ISOCITRATE DEHYDROGENASE 1;

ADAPTIVE IMMUNITY; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; DNA DAMAGE; EXCITOTOXICITY; GENE MUTATION; GLIOMA; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; MEDIATOR RELEASE; METASTASIS; MICROGLIA; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; BRAIN TUMOR; COMPLICATION; DISEASE COURSE; ENCEPHALITIS; MACROPHAGE; METABOLISM;

ANIMALS; BRAIN NEOPLASMS; DISEASE PROGRESSION; ENCEPHALITIS; GLIOMA; HUMANS; INFLAMMATION; MACROPHAGES;

EID: 84973342031     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2016.05.019     Document Type: Review

References (93)

1. Abou-Ghazal M., Yang D.S., Qiao W., Reina-Ortiz C., Wei J., Kong L.Y., Fuller G.N., Hiraoka N., Priebe W., Sawaya R., Heimberger A.B. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin. Cancer Res. 2008, 14(24):8228-8235.
2. Aghili M., Zahedi F., Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neuro-Oncol. 2009, 91(2):233-236.
3. Alterman R.L., Stanley E.R. Colony stimulating factor-1 expression in human glioma. Mol. Chem. Neuropathol. 1994, 21(2-3):177-188.
4. Anthony D.C., Bolton S.J., Fearn S., Perry V.H. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997, 120(Pt 3):435-444.
5. Bach J.P., Deuster O., Balzer-Geldsetzer M., Meyer B., Dodel R., Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009, 115(10):2031-2040.
6. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545. (London, England).
7. Blank T., Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2013, 61(1):62-70.
8. Brabers N.A., Nottet H.S. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur. J. Clin. Investig. 2006, 36(7):447-458.
9. Cairncross J.G., Wang M., Jenkins R.B., Shaw E.G., Giannini C., Brachman D.G., Buckner J.C., Fink K.L., Souhami L., Laperriere N.J., Huse J.T., Mehta M.P., Curran W.J. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32(8):783-790.
10. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 59(8):1169-1180.
11. Christofides A., Kosmopoulos M., Piperi C. Pathophysiological mechanisms regulated by cytokines in gliomas. Cytokine 2015, 71(2):377-384.
12. Cohen A., Holmen S., Colman H. IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep. 2013, 13(5). (pp. 345-013-0345-4).
13. Coniglio S.J., Eugenin E., Dobrenis K., Stanley E.R., West B.L., Symons M.H., Segall J.E. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 2012, 18:519-527.
14. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
15. Czlonkowska A., Kurkowska-Jastrzebska I. Inflammation and gliosis in neurological diseases-clinical implications. J. Neuroimmunol. 2011, 231(1-2):78-85.
16. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993, 178(3):1041-1048.
17. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465(7300):966.
18. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991, 174(5):1209-1220.
19. Ding P., Wang W., Wang J., Yang Z., Xue L. Expression of tumor-associated macrophage in progression of human glioma. Cell Biochem. Biophys. 2014, 70(3):1625-1631.
20. Duluc D., Delneste Y., Tan F., Moles M.P., Grimaud L., Lenoir J., Preisser L., Anegon I., Catala L., Ifrah N., Descamps P., Gamelin E., Gascan H., Hebbar M., Jeannin P. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110(13):4319-4330.
21. Eckel-Passow J.E., Lachance D.H., Molinaro A.M., Walsh K.M., Decker P.A., Sicotte H., Pekmezci M., Rice T., Kosel M.L., Smirnov I.V., Sarkar G., Caron A.A., Kollmeyer T.M., Praska C.E., Chada A.R., Halder C., Hansen H.M., McCoy L.S., Bracci P.M., Marshall R., Zheng S., Reis G.F., Pico A.R., O'Neill B.P., Buckner J.C., Giannini C., Huse J.T., Perry A., Tihan T., Berger M.S., Chang S.M., Prados M.D., Wiemels J., Wiencke J.K., Wrensch M.R., Jenkins R.B. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 2015, 372(26):2499-2508.
22. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767.
23. Fogal B., Hewett S.J. Interleukin-1beta: a bridge between inflammation and excitotoxicity?. J. Neurochem. 2008, 106(1):1-23.
24. Frei K., Piani D., Malipiero U.V., Van Meir E., de Tribolet N., Fontana A. Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo. J. Immunol. 1992, 148(10):3140-3146. (Baltimore, Md.: 1950).
25. Frontczak-Baniewicz M., Chrapusta S.J., Sulejczak D. Long-term consequences of surgical brain injury - characteristics of the neurovascular unit and formation and demise of the glial scar in a rat model. Folia Neuropathol. 2011, 49(3):204-218.
26. Gabrusiewicz K., Ellert-Miklaszewska A., Lipko M., Sielska M., Frankowska M., Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS ONE 2011, 6(8):e23902.
27. Gabrusiewicz K., Hossain M.B., Cortes-Santiago N., Fan X., Kaminska B., Marini F.C., Fueyo J., Gomez-Manzano C. Macrophage ablation reduces M2-like populations and jeopardizes tumor growth in a MAFIA-based glioma model. Neoplasia 2015, 17(4):374-384. (New York, N.Y.).
28. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R., Samokhvalov I.M., Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (New York, N.Y.) 2010, 330(6005):841-845.
29. Gonda D.D., Cheung V.J., Muller K.A., Goyal A., Carter B.S., Chen C.C. The cancer genome atlas expression profiles of low-grade gliomas. Neurosurg. Focus. 2014, 36(4):E23.
30. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
31. Ha E.T., Antonios J.P., Soto H., Prins R.M., Yang I., Kasahara N., Liau L.M., Kruse C.A. Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunol. Neuroinflammation 2014, 1(2):66.
32. Hamard L., Ratel D., Selek L., Berger F., van der Sanden B., Wion D. The brain tissue response to surgical injury and its possible contribution to glioma recurrence. J. Neuro-Oncol. 2016.
33. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
34. Huang H., Colella S., Kurrer M., Yonekawa Y., Kleihues P., Ohgaki H. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 2000, 60(24):6868-6874.
35. Huettner C., Paulus W., Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol. 1995, 146(2):317-322.
36. Huettner C., Czub S., Kerkau S., Roggendorf W., Tonn J.C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 1997, 17(5 A):3217-3224.
37. Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 2006, 8(3):261-279.
38. Jaeckle K.A., Decker P.A., Ballman K.V., Flynn P.J., Giannini C., Scheithauer B.W., Jenkins R.B., Buckner J.C. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J. Neuro-Oncol. 2011, 104(1):253-259.
39. Jander S., Schroeter M., Stoll G. Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. J. Neuroimmunol. 2000, 109(2):181-187.
40. Juedes A.E., Ruddle N.H. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J. Immunol. 2001, 166(8):5168-5175. (Baltimore, MD: 1950).
41. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501(7467):346-354.
42. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441(7092):431-436.
43. Kennedy B.C., Showers C.R., Anderson D.E., Anderson L., Canoll P., Bruce J.N., Anderson R.C. Tumor-associated macrophages in glioma: friend or foe?. J. Oncol. 2013, 2013:486912.
44. Kolker S., Mayatepek E., Hoffmann G.F. White matter disease in cerebral organic acid disorders: clinical implications and suggested pathomechanisms. Neuropediatrics 2002, 33(5):225-231.
45. Komohara Y., Hirahara J., Horikawa T., Kawamura K., Kiyota E., Sakashita N., Araki N., Takeya M. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J. Histochem. Cytochem. 2006, 54(7):763-771.
46. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216(1):15-24.
47. Ku M.C., Wolf S.A., Respondek D., Matyash V., Pohlmann A., Waiczies S., Waiczies H., Niendorf T., Synowitz M., Glass R., Kettenmann H. GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis. Acta Neuropathol. 2013, 125(4):609-620.
48. Labussiere M., Idbaih A., Wang X.W., Marie Y., Boisselier B., Falet C., Paris S., Laffaire J., Carpentier C., Criniere E., Ducray F., El Hallani S., Mokhtari K., Hoang-Xuan K., Delattre J.Y., Sanson M. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010, 74(23):1886-1890.
49. Leung S.Y., Wong M.P., Chung L.P., Chan A.S., Yuen S.T. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol. 1997, 93(5):518-527.
50. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193(6):727-740.
51. Lisi L., Laudati E., Navarra P., Dello Russo C. The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J. Neuroinflammation 2014, 11. (pp. 125-2094-11-125).
52. Lisi L., Stigliano E., Lauriola L., Navarra P., Dello Russo C. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro 2014, 6(3):171-183.
53. Locatelli M., Ferrero S., Martinelli Boneschi F., Boiocchi L., Zavanone M., Maria Gaini S., Bello L., Valentino S., Barbati E., Nebuloni M., Mantovani A., Garlanda C. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J. Neuroimmunol. 2013, 260(1-2):99-106.
54. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2):97-109.
55. Lu-Emerson C., Snuderl M., Kirkpatrick N.D., Goveia J., Davidson C., Huang Y., Riedemann L., Taylor J., Ivy P., Duda D.G., Ancukiewicz M., Plotkin S.R., Chi A.S., Gerstner E.R., Eichler A.F., Dietrich J., Stemmer-Rachamimov A.O., Batchelor T.T., Jain R.K. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology 2013, 15(8):1079-1087.
56. Luscher U., Filgueira L., Juretic A., Zuber M., Luscher N.J., Heberer M., Spagnoli G.C. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer 1994, 57(4):612-619.
57. Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 1992, 13(7):265-270.
58. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23(11):549-555.
59. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25(12):677-686.
60. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
61. Okada M., Saio M., Kito Y., Ohe N., Yano H., Yoshimura S., Iwama T., Takami T. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int. J. Oncol. 2009, 34(6):1621-1627.
62. Park C.K., Kim J.H., Moon M.J., Jung J.H., Lim S.Y., Park S.H., Kim J.H., Kim D.G., Jung H.W., Cho B.K., Paek S.H. Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J. Cancer Res. Clin. Oncol. 2008, 134(2):255-262.
63. Park C.K., Park I., Lee S., Sun C.H., Koh Y., Park S.H., Kim J.E., Yun H., Lee S.H. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. Oncotarget 2015.
64. Parkhurst C.N., Yang G., Ninan I., Savas J.N., Yates J.R., Lafaille J.J., Hempstead B.L., Littman D.R., Gan W.B. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013, 155(7):1596-1609.
65. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4(1):71-78.
66. Prinz M., Priller J., Sisodia S.S., Ransohoff R.M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011, 14(10):1227-1235.
67. Prosniak M., Harshyne L.A., Andrews D.W., Kenyon L.C., Bedelbaeva K., Apanasovich T.V., Heber-Katz E., Curtis M.T., Cotzia P., Hooper D.C. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin. Cancer Res. 2013, 19(14):3776-3786.
68. Qiu B., Zhang D., Wang C., Tao J., Tie X., Qiao Y., Xu K., Wang Y., Wu A. IL-10 and TGF-beta2 are overexpressed in tumor spheres cultured from human gliomas. Mol. Biol. Rep. 2011, 38(5):3585-3591.
69. Rakoff-Nahoum S. Why cancer and inflammation?. Yale J. Biol. Med. 2006, 79(3-4):123-130.
70. Roussel E., Gingras M.C., Grimm E.A., Bruner J.M., Moser R.P. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin. Exp. Immunol. 1996, 105(2):344-352.
71. Salmaggi A., Gelati M., Pollo B., Marras C., Silvani A., Balestrini M.R., Eoli M., Fariselli L., Broggi G., Boiardi A. CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J. Neuro-Oncol. 2005, 74(3):287-293.
72. Samaras V., Piperi C., Korkolopoulou P., Zisakis A., Levidou G., Themistocleous M.S., Boviatsis E.I., Sakas D.E., Lea R.W., Kalofoutis A., Patsouris E. Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol. Cell. Biochem. 2007, 304(1-2):343-351.
73. Sayour E.J., McLendon P., McLendon R., De Leon G., Reynolds R., Kresak J., Sampson J.H., Mitchell D.A. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol. Immunother. 2015, 64(4):419-427.
74. Schomas D.A., Laack N.N., Rao R.D., Meyer F.B., Shaw E.G., O'Neill B.P., Giannini C., Brown P.D. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-Oncology 2009, 11(4):437-445.
75. Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., Prinz M., Wu B., Jacobsen S.E., Pollard J.W., Frampton J., Liu K.J., Geissmann F. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science (New York, N.Y.) 2012, 336(6077):86-90.
76. Sielska M., Przanowski P., Wylot B., Gabrusiewicz K., Maleszewska M., Kijewska M., Zawadzka M., Kucharska J., Vinnakota K., Kettenmann H., Kotulska K., Grajkowska W., Kaminska B. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J. Pathol. 2013, 230(3):310-321.
77. Smith J.S., Chang E.F., Lamborn K.R., Chang S.M., Prados M.D., Cha S., Tihan T., Vandenberg S., McDermott M.W., Berger M.S. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26(8):1338-1345.
78. Soehnlein O., Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat. Rev. Immunol. 2010, 10(6):427-439.
79. Sowers J.L., Johnson K.M., Conrad C., Patterson J.T., Sowers L.C. The role of inflammation in brain cancer. Adv. Exp. Med. Biol. 2014, 816:75-105.
80. Tanabe K., Kozawa O., Iida H. cAMP/PKA enhances interleukin-1beta-induced interleukin-6 synthesis through STAT3 in glial cells. Cell. Signal. 2016, 28(1):19-24.
81. Tracey K.J., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 1993, 9:317-343.
82. Ulvestad E., Williams K., Bjerkvig R., Tiekotter K., Antel J., Matre R. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J. Leukoc. Biol. 1994, 56(6):732-740.
83. Vakkila J., Lotze M.T. Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 2004, 4(8):641-648.
84. Vlahovic G., Fecci P.E., Reardon D., Sampson J.H. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro-Oncology 2015, 17(8):1043-1045.
85. Voehringer D., Shinkai K., Locksley R.M. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 2004, 20(3):267-277.
86. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R., Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390(6658):350-351.
87. Wajner M., Latini A., Wyse A.T., Dutra-Filho C.S. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J. Inherit. Metab. Dis. 2004, 27(4):427-448.
88. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009, 174(4):1149-1153.
89. Watters J.J., Schartner J.M., Badie B. Microglia function in brain tumors. J. Neurosci. Res. 2005, 81(3):447-455.
90. Wei J., Gabrusiewicz K., Heimberger A. The controversial role of microglia in malignant gliomas. Clin. Dev. Immunol. 2013, 2013:285246.
91. Wu A., Wei J., Kong L.Y., Wang Y., Priebe W., Qiao W., Sawaya R., Heimberger A.B. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology 2010, 12(11):1113-1125.
92. Xu W., Schlagwein N., Roos A., van den Berg T.K., Daha M.R., van Kooten C. Human peritoneal macrophages show functional characteristics of M-CSF-driven anti-inflammatory type 2 macrophages. Eur. J. Immunol. 2007, 37(6):1594-1599.
93. Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., Hume D.A., Perlman H., Malissen B., Zelzer E., Jung S. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38(1):79-91.